Reminder: An ALZ drug class that is able to cut beta amyloid to a targeted baseline, but only mildly slows the progression of ALZ, is not really doing anything.
And that comes with the risk of 1 in 4 patients with brain inflammation or bleeding. Then there's the issue of widespread brain shrinkage and a higher than normal risk of death.
All that, for hundreds of thousands of dollars of treatment.
Targeting amyloid is not the answer. To believe otherwise is to not trust the data.
Spin D'Accord /
npub1ez…985cp
2023-05-04 14:53:03
Author Public Key
npub1ezcwm2jg6njyg6vqxh8jvhlc34wz5cvxhgv758za74wp4djqxlxq5985cpPublished at
2023-05-04 14:53:03Event JSON
{
"id": "8e04076a72570806f05277b4bcb3b0c5c6ecaf548d6ec458cc5e5ae1d47326ae",
"pubkey": "c8b0edaa48d4e444698035cf265ff88d5c2a6186ba19ea1c5df55c1ab64037cc",
"created_at": 1683211983,
"kind": 1,
"tags": [
[
"mostr",
"https://mas.to/users/gkmizuno/statuses/110310980544362709"
]
],
"content": "Reminder: An ALZ drug class that is able to cut beta amyloid to a targeted baseline, but only mildly slows the progression of ALZ, is not really doing anything.\n\nAnd that comes with the risk of 1 in 4 patients with brain inflammation or bleeding. Then there's the issue of widespread brain shrinkage and a higher than normal risk of death.\n\nAll that, for hundreds of thousands of dollars of treatment.\n\nTargeting amyloid is not the answer. To believe otherwise is to not trust the data.",
"sig": "0d4e1e55cade2743fe7d51af29212738b31e1421b27c22ab524c18d64b22e48bcf7948cebfb4e221c734370f58168de0d12c35fe307ebcb956dcc02cc1c7c59b"
}